What's fueling the biotech engine--2008.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 19898448.
- Also identified by DOI 10.1038/nbt1109-987.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Despite the global economic slowdown, biologics managed single-digit growth in 2008, driven mainly by continued high growth in sales of antibodies and insulins. Novel biologics in development look promising, but crowding, pricing and reimbursement are emerging as longer-term concerns.
Medical subject headings
- Biotechnology